

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-11 (Cancelled).

12 (Currently amended). A composition for treating ~~herpes-group~~ viral infections, said composition comprising non-specifically activated autologous lymphocytes effective against ~~and specific for herpes-group viral infections~~, said activated autologous lymphocytes being obtained by culturing autologous lymphocytes derived from a ~~herpes-group~~ virally infected patient, ~~or an immunodeficient or immunosuppressed patient due to herpes group viral infection~~, in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said autologous lymphocytes, ~~said virally infected patient or said immunodeficient or immunosuppressed patient to be provided with said composition.~~

13 (Currently amended). A method for preparing a composition for treating a viral infection ~~herpes-group viral infections~~, said method comprising deriving autologous lymphocytes from a ~~herpes-group~~ virally infected patient ~~or an immunodeficient or immunosuppressed patient due to herpes group viral infection~~, ~~to be provided with said composition~~, and

culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and non-specifically activate *in vitro* said autologous lymphocytes ~~which are effective against and specific for herpes group viral infections.~~

14(Currently amended). A method for treating a viral infection ~~herpes group viral infections~~, said method comprising deriving autologous lymphocytes from a ~~herpes group virally~~ infected patient, ~~or an immunodeficient or immunosuppressed patient due to herpes group viral infection~~, culturing said autologous lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and non-specifically activate *in vitro* said autologous lymphocytes, and administering said non-specifically activated autologous lymphocytes ~~which are effective against and specific for herpes group viral infections~~ to said patient ~~from which said autologous lymphocytes were derived.~~

15(Currently amended). The composition according to claim 12, wherein said activated autologous lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

16(Previously presented). The composition according to claim 15, wherein a protein is added to said cell-suspended solution.

17(Previously presented). The composition according to claim 16, wherein said protein is human albumin.

18(Previously presented). The composition to claim 12, wherein said culture medium further comprises cytokine.

19(Currently amended). The method according to claim 13, wherein said activated ~~autologous~~ lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

20(Previously presented). The method according to claim 19, wherein a protein is added to said cell-suspended solution.

21(Previously presented). The method according to claim 20, wherein said protein is human albumin.

22(Previously presented). The method according to claim 13, wherein said culture medium further comprises cytokines.

23(Currently amended). The method according to claim 14, wherein said activated ~~autologous~~ lymphocytes cultivated *in vitro* are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

24(Previously presented). The method according to claim 23, wherein a protein is added to said cell-suspended solution.

25(Previously presented). The method according to claim 24, wherein said protein is human albumin.

26(Currently amended). The method according to claim 23, wherein said activated ~~autologous~~ lymphocytes having a cell concentration in the range of 1×10^4 parts/lit. to 1×10^8 parts/lit. are administered to same patient at a time.

27(Previously presented). The method according to claim 23, wherein said culture medium further comprises cytokines.

Claims 28-30 (Cancelled).

31(Currently amended). The method according to claim 13, wherein said ~~herpes-group~~ viral infection is an Epstein-Barr ~~virus~~ viral infection.

32(Currently amended). The method according to claim 14, wherein said patient is virally infected, immunodeficient or immunosuppressed due to an Epstein-Barr ~~virus~~ viral infection.

Claim 33 (Cancelled).

34(Currently amended). The method according to claim 13, wherein said ~~herpes-group~~ viral infection is a herpes simplex ~~virus~~ viral infection.

35(Currently amended). The composition according to claim 12, wherein the activated ~~autologous~~ lymphocytes are T-lymphocytes.

36(Currently amended). The method according to claim 13, wherein the activated ~~autologous~~ lymphocytes are T-lymphocytes.

37(Currently amended). The method according to claim 14, wherein the activated ~~autologous~~ lymphocytes are T-lymphocytes.

38(New). The method according to claim 13, wherein the viral infection is a herpes group viral infection.

39(New). The method according to claim 14, wherein the viral infection is a herpes group viral infection.